Sildenafil in Infants and Children

Area of Science:

• Pediatric Cardiology
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) management has advanced with new diagnostics and therapies.
• Sildenafil, a phosphodiesterase-V inhibitor, is a primary treatment for adult and pediatric pulmonary hypertension (PH).
• Its use extends to various pediatric PH conditions, including persistent pulmonary hypertension of the newborn (PPHN) and bronchopulmonary dysplasia.

Purpose of the Study:

• To review the current landscape of pulmonary hypertension in infants and children.
• To summarize the role and application of Sildenafil in treating pediatric PH.
• To discuss the implications of recent data and regulatory changes on Sildenafil's use.

Main Methods:

• Literature review of studies on pediatric pulmonary hypertension.
• Analysis of Sildenafil's efficacy and safety data in pediatric populations.
• Examination of treatment guidelines and regulatory updates concerning Sildenafil.

Main Results:

• Sildenafil is a widely adopted first-line treatment for pediatric PH.
• Its efficacy has been demonstrated across various pediatric PH subtypes.
• Recent data on long-term mortality and FDA approval status present complexities but do not diminish its current clinical importance.

Conclusions:

• Sildenafil remains a cornerstone therapy for pediatric pulmonary hypertension.
• Despite evolving data, it is expected to remain a primary treatment option.
• This review provides a comprehensive overview of pediatric PH and Sildenafil's therapeutic role.